newsfilter
← Latest News
Business Wire·

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto")